Pfizer to combine off-patent drug business with Mylan

Pfizer announced Monday it will combine its off-patent drug business with the generic drugmaker Mylan to create a global leader in low-cost treatment, as drugmakers face intense political pressure to drive down prices in the United States.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/pfizer-to-combine-off-patent-drug-business-with-mylan